Accelerate Diagnostics (AXDX) vs. PerkinElmer (PKI) Financial Analysis

Accelerate Diagnostics (NASDAQ: AXDX) and PerkinElmer (NYSE:PKI) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, profitability, risk and earnings.

Insider & Institutional Ownership

47.9% of Accelerate Diagnostics shares are held by institutional investors. Comparatively, 91.4% of PerkinElmer shares are held by institutional investors. 50.0% of Accelerate Diagnostics shares are held by insiders. Comparatively, 2.2% of PerkinElmer shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Accelerate Diagnostics and PerkinElmer’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Accelerate Diagnostics -3,085.36% -60.99% -57.85%
PerkinElmer 18.27% 13.11% 6.82%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Accelerate Diagnostics and PerkinElmer, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Accelerate Diagnostics 0 1 1 0 2.50
PerkinElmer 1 9 5 0 2.27

Accelerate Diagnostics currently has a consensus price target of $33.00, suggesting a potential upside of 12.82%. PerkinElmer has a consensus price target of $71.23, suggesting a potential downside of 6.72%. Given Accelerate Diagnostics’ stronger consensus rating and higher possible upside, analysts plainly believe Accelerate Diagnostics is more favorable than PerkinElmer.

Valuation and Earnings

This table compares Accelerate Diagnostics and PerkinElmer’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Accelerate Diagnostics $250,000.00 6,481.80 -$66.37 million ($1.20) -24.37
PerkinElmer $2.12 billion 3.98 $234.29 million $2.21 34.55

PerkinElmer has higher revenue and earnings than Accelerate Diagnostics. Accelerate Diagnostics is trading at a lower price-to-earnings ratio than PerkinElmer, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Accelerate Diagnostics has a beta of 2.18, suggesting that its share price is 118% more volatile than the S&P 500. Comparatively, PerkinElmer has a beta of 0.77, suggesting that its share price is 23% less volatile than the S&P 500.

Dividends

PerkinElmer pays an annual dividend of $0.28 per share and has a dividend yield of 0.4%. Accelerate Diagnostics does not pay a dividend. PerkinElmer pays out 12.7% of its earnings in the form of a dividend.

Summary

PerkinElmer beats Accelerate Diagnostics on 10 of the 16 factors compared between the two stocks.

Accelerate Diagnostics Company Profile

Accelerate Diagnostics, Inc. is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company’s in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. It detects and identifies pathogens directly from a single patient sample followed by antimicrobial susceptibility testing based on the identification results. The Accelerate PhenoTest BC Kit provides ID and AST results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The Accelerate Pheno system features walk-away automation and consists of a fixed instrument and single-use test kit.

PerkinElmer Company Profile

PerkinElmer, Inc. is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment serves the environmental, food, industrial, life sciences research and laboratory services markets. It provides analytical instrumentation for the industrial market, which includes the chemical, electronics, energy, lubricant, petrochemical and polymer industries. Its products include AAnalyst, Altus, Aquamatic, Avio, AxION, Clarus, DairyGuard, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, Cell carrier and cell::explorer. The Diagnostics segment is focused on reproductive health, emerging market diagnostics and applied genomics. Its products include AutoDELFIA, BACS-on-Beads, Bioo Scientific, BoBs, Datalytix, Dexela, Dexela CMOS FPDs, Evolution, ViaCord, and Zephyr.

Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.